229 related articles for article (PubMed ID: 7668537)
1. Interleukin-6-type cytokines and their receptors for gene therapy of melanoma.
Mackiewicz A; Wiznerowicz M; Roeb E; Nowak J; Pawlowski T; Baumann H; Heinrich PC; Rose-John S
Ann N Y Acad Sci; 1995 Jul; 762():361-73; discussion 373-4. PubMed ID: 7668537
[TBL] [Abstract][Full Text] [Related]
2. Soluble interleukin 6 receptor is biologically active in vivo.
Mackiewicz A; Wiznerowicz M; Roeb E; Karczewska A; Nowak J; Heinrich PC; Rose-John S
Cytokine; 1995 Feb; 7(2):142-9. PubMed ID: 7780033
[TBL] [Abstract][Full Text] [Related]
3. Soluble gp130 is up-regulated in the implantation window and shows altered secretion in patients with primary unexplained infertility.
Sherwin JR; Smith SK; Wilson A; Sharkey AM
J Clin Endocrinol Metab; 2002 Aug; 87(8):3953-60. PubMed ID: 12161539
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and in cladribine induced remission.
Robak T; Wierzbowska A; Błasińska-Morawiec M; Korycka A; Błoński JZ
Mediators Inflamm; 1999; 8(6):277-86. PubMed ID: 10815616
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of interleukin 6 receptors of mouse myelomonocytic leukemic cells by leukemia inhibitory factor.
Yamaguchi M; Michishita M; Hirayoshi K; Yasukawa K; Okuma M; Nagata K
J Biol Chem; 1992 Nov; 267(31):22035-42. PubMed ID: 1429553
[TBL] [Abstract][Full Text] [Related]
6. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae.
Palmqvist P; Persson E; Conaway HH; Lerner UH
J Immunol; 2002 Sep; 169(6):3353-62. PubMed ID: 12218157
[TBL] [Abstract][Full Text] [Related]
7. Circulating IL-6-type cytokines and sIL-6R in patients with multiple myeloma.
Wierzbowska A; Urbańska-Ryś H; Robak T
Br J Haematol; 1999 May; 105(2):412-9. PubMed ID: 10233412
[TBL] [Abstract][Full Text] [Related]
8. Maintenance of the pluripotential phenotype of embryonic stem cells through direct activation of gp130 signalling pathways.
Yoshida K; Chambers I; Nichols J; Smith A; Saito M; Yasukawa K; Shoyab M; Taga T; Kishimoto T
Mech Dev; 1994 Feb; 45(2):163-71. PubMed ID: 8199053
[TBL] [Abstract][Full Text] [Related]
9. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family.
Mihara M; Kasutani K; Okazaki M; Nakamura A; Kawai S; Sugimoto M; Matsumoto Y; Ohsugi Y
Int Immunopharmacol; 2005 Nov; 5(12):1731-40. PubMed ID: 16102523
[TBL] [Abstract][Full Text] [Related]
10. Leukemia inhibitory factor, interleukin-6, and their receptors are expressed transiently in the olfactory mucosa after target ablation.
Nan B; Getchell ML; Partin JV; Getchell TV
J Comp Neurol; 2001 Jun; 435(1):60-77. PubMed ID: 11370011
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis.
Robak T; Gladalska A; Stepień H; Robak E
Mediators Inflamm; 1998; 7(5):347-53. PubMed ID: 9883970
[TBL] [Abstract][Full Text] [Related]
12. The designer cytokine hyper-IL-6 mediates growth inhibition and GM-CSF-dependent rejection of B16 melanoma cells.
Ozbek S; Peters M; Breuhahn K; Mann A; Blessing M; Fischer M; Schirmacher P; Mackiewicz A; Rose-John S
Oncogene; 2001 Feb; 20(8):972-9. PubMed ID: 11314032
[TBL] [Abstract][Full Text] [Related]
13. Sequence, expression and function of an mRNA encoding a soluble form of the human interleukin-6 receptor (sIL-6R).
Lust JA; Jelinek DF; Donovan KA; Frederick LA; Huntley BK; Braaten JK; Maihle NJ
Curr Top Microbiol Immunol; 1995; 194():199-206. PubMed ID: 7895493
[TBL] [Abstract][Full Text] [Related]
14. Coadministration of interleukin-6 (IL-6) and soluble IL-6 receptor delays progression of wobbler mouse motor neuron disease.
Ikeda K; Kinoshita M; Tagaya N; Shiojima T; Taga T; Yasukawa K; Suzuki H; Okano A
Brain Res; 1996 Jul; 726(1-2):91-7. PubMed ID: 8836549
[TBL] [Abstract][Full Text] [Related]
15. Oncostatin M is a differentiation factor for myeloid leukemia cells.
Bruce AG; Hoggatt IH; Rose TM
J Immunol; 1992 Aug; 149(4):1271-5. PubMed ID: 1380037
[TBL] [Abstract][Full Text] [Related]
16. Distinctive pro-inflammatory gene signatures induced in articular chondrocytes by oncostatin M and IL-6 are regulated by Suppressor of Cytokine Signaling-3.
Liu X; Liu R; Croker BA; Lawlor KE; Smyth GK; Wicks IP
Osteoarthritis Cartilage; 2015 Oct; 23(10):1743-54. PubMed ID: 26045176
[TBL] [Abstract][Full Text] [Related]
17. Chimeric cytokine receptor can transduce expansion signals in interleukin 6 receptor alpha (IL-6Ralpha)-, IL-11Ralpha-, and gp130-low to -negative primitive hematopoietic progenitors.
Takagi M; Nakamura T; Sawada T; Kaneko A; Nozaki-Ukai M; Nakahata T; Yokota T; Heike T
Mol Biol Cell; 1999 Nov; 10(11):3633-42. PubMed ID: 10564261
[TBL] [Abstract][Full Text] [Related]
18. Differential temporal expression of mRNAs for ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF), interleukin-6 (IL-6), and their receptors (CNTFR alpha, LIFR beta, IL-6R alpha and gp130) in injured peripheral nerves.
Ito Y; Yamamoto M; Li M; Doyu M; Tanaka F; Mutch T; Mitsuma T; Sobue G
Brain Res; 1998 May; 793(1-2):321-7. PubMed ID: 9630704
[TBL] [Abstract][Full Text] [Related]
19. Endothelial cell protein S synthesis is upregulated by the complex of IL-6 and soluble IL-6 receptor.
Hooper WC; Phillips DJ; Evatt BL
Thromb Haemost; 1997 May; 77(5):1014-9. PubMed ID: 9184420
[TBL] [Abstract][Full Text] [Related]
20. Immunoassay for functional human soluble interleukin-6 receptor in plasma based on ligand/receptor interactions.
Montero-Julian FA; Liautard J; Flavetta S; Romagné F; Gaillard JP; Brochier J; Klein B; Brailly H
J Immunol Methods; 1994 Feb; 169(1):111-21. PubMed ID: 8133069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
